Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences reported Q3 2020 sales of $1.1 billion, a 4% increase from the previous year, with a strong performance in TAVR, which grew 6% to $745 million. Adjusted EPS rose 9% to $0.51, prompting an increase in full-year EPS guidance to $1.85-$1.95. The company noted significant growth potential in TMTT therapies, with $12 million in sales. Overall gross margin was 75.5%. The fourth quarter outlook suggests similar growth to Q3, and the company anticipates double-digit growth in TAVR sales for 2021.
Edwards Lifesciences is set to announce its operating results for the quarter ending September 30, 2020, after market close on October 21, 2020. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can join the call by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be available for 72 hours post-call. Further details can be accessed on the company's Investor Relations website.
Edwards Lifesciences (NYSE: EW) announced FDA approval for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. This innovative device utilizes RESILIA tissue technology, enhancing valve durability and simplifying surgical procedures. The KONECT device aims to streamline emergency surgeries, as up to 30% of Bentall procedures occur in urgent situations. Edwards continues to lead in patient-focused innovations for structural heart disease and is committed to improving patient outcomes through advanced technologies.
On July 13, 2020, Edwards Lifesciences announced a settlement with Abbott to resolve all patent disputes related to transcatheter mitral and tricuspid repair products. This agreement will lift all injunctions and dismiss pending cases worldwide for ten years, allowing Edwards to focus on patient care without litigation distractions. The company will incur a one-time settlement expense in Q2 2020 and ongoing royalty expenses through May 2024. The details of the settlement are confidential, enhancing Edwards' position in the market.
Edwards Lifesciences Corporation (NYSE: EW) will announce its operating results for Q2 2020 on July 23, 2020, after the market closes. A conference call will follow at 5:00 p.m. ET to discuss these results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be available for 72 hours post-call. Edwards is a leader in patient-focused innovations for structural heart disease and critical care monitoring, aiming to enhance patient lives through partnerships with healthcare stakeholders.
Summary not available.